Intern, Upstream Process Development

  • 35 Cambridgepark Dr, Cambridge, MA 02140, USA
  • Intern

Company Description

Codiak is the leader in the emerging field of exosome therapeutics, working to harness the power of this cellular messenger system to create potentially life-changing medicines. A venture-backed startup founded in 2015, Codiak has rapidly built a proprietary technology platform for exosome engineering and manufacturing that allows for precise targeting of important molecular pathways, opening the door to the development of therapies for cancer and other diseases. Led by an experienced and dedicated team, Codiak has at its foundation a positive and collaborative culture that is deeply rooted in cutting edge science and promotes opportunity for growth.

Job Description

Project Summary: 

The upstream process development (USP) team generates large amounts of discrete and continuous data as part of routine bioprocess monitoring. The USP team is seeking a data analyst to implement and roll out a SQL database integrated with a web-app, Seeq, to help streamline data analysis. This project would involve configuring a SQL database, integrating it with the Seeq server, testing and troubleshooting the software-database communication with historical data, then rolling out capabilities to the group via training and documentation.

Skills Acquired:

The intern would gain the following skills by completing this project:

  • SQL database management, design, and integration
  • Upstream bioprocess data analysis
  • Knowledge of OPC systems (DeltaV)
  • Seeq software and experience working with an external vendor
  • Technical writing

Qualifications

Preferred Skills

  • Knowledge of SQL
  • Computer science/ programing background
  • Math skills (calculus and/or statistics)

Additional Information

About Codiak

Forward Engineering on Nature’s Messenger System

Recent discoveries have demonstrated that exosomes derived from normal cells can act as a potent and safe delivery system for multiple therapeutic payloads. These small vesicles, which leave cells and travel throughout the body, can mediate dramatic effects in animal models of disease.

We are developing a broad platform for the delivery of macromolecules to the cytoplasm of diverse cells and tissues, to create a proprietary pipeline of novel, targeted medicines for diseases with high unmet medical need. The company’s technology exploits the natural propensity of exosomes to transmit macromolecule payloads between cells to create a pipeline of drugs across a broad range of diseases, including those associated with currently “undruggable” targets. While our initial focus is on oncology/immuno-oncology, this approach also offers significant potential in hematology, neurology and gene therapy  and other therapy areas.

We are now producing drug candidate exosomes using the engExTM platform, our novel therapeutic engine for exosomes. We tailor exosomes to express molecules on their surfaces and/or deliver specific cargo inside. This affords us the flexibility for designing proprietary drug candidates; exosomes can be mixed and matched into rational and targeted combinations with the potential for a broad therapeutic platform.

As of December 2017, Codiak has raised a combined $168.5M in Series A-C financing. The company maintains partnerships with academic exosome labs and has multiple paths to clinical and commercial success through the breadth of the company’s research, strength of its IP position and proprietary innovation behind its production capabilities.

Inspired Employees Create Great Science

Codiak’s CEO and first employee Doug Williams, Ph.D., (former EVP of Biogen R&D, CEO of ZymoGenetics) espouses the belief that inspired employees create great science. Employees treat the company as if it was their own and report that there is “direct and respectful communication,”  and “trust that teammates will do the right thing and never compromise integrity.”  

Named one of 11 disruptive startups “on a do-or-die mission to launch new meds” by Endpoints News in January 2018, Codiak is in the heart of Boston’s biotechnology hub at 500 Technology Square in Cambridge, Massachusetts.

 

Website: www.codiakbio.com

Codiak BioSciences is an Equal Opportunity Employer committed to a culturally diverse workforce. All qualified applicants will receive consideration for employment without regard to race; color; creed; religion; national origin; age; ancestry; nationality; marital, domestic partnership or civil union status; sex, gender, gender identity or expression; affectional or sexual orientation; disability; veteran or military status or liability for military status.